Metagenomi, Inc. operates as a biotechnology company focused on gene editing, committed to developing therapeutic solutions for patients. The company utilizes a distinctive genome editing toolkit, sourced from metagenomics, for its development efforts within the United States. This advanced toolkit comprises programmable nucleases, base editors, and sophisticated RNA and DNA-mediated integration systems, notably prime editing and CRISPR-associated transposases. Metagenomi has established several key collaborations: a strategic alliance with ModernaTX, Inc. to explore new genome editing systems for in vivo human therapeutic applications; a development and licensing agreement with Affini-T Therapeutics, Inc. to create and commercialize gene-edited T-cell receptor therapies for human cancer; and a partnership with Ionis Pharmaceuticals, Inc. to research, develop, and market investigational medicines leveraging genome editing technologies. Founded in 2016, the company is based in Emeryville, California.
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|
| Revenue | $52.30M | $44.76M | $17.20M | $243.00K |
| Cost of Revenue | N/A | $94.40M | $1.73M | $387.00K |
| Gross Profit | $52.30M | $-49.65M | $15.47M | $-144.00K |
| Gross Margin | 100.00% | -110.93% | 89.92% | -59.26% |
| Operating Expenses | $141.20M | $28.84M | $60.11M | $23.80M |
| Operating Income | $-88.90M | $-78.49M | $-44.64M | $-23.95M |
| Operating Margin | -170.00% | -175.38% | -259.53% | -9854.73% |
| Net Income | $-78.06M | $-68.25M | $-43.59M | $-21.44M |
| Net Margin | -149.26% | -152.50% | -253.45% | -8823.87% |
| EPS (Basic) | $-2.09 | $-1.82 | $-1.16 | $-3.62 |
| EBITDA | N/A | N/A | N/A | N/A |
| Stock Option Compensation Expense | N/A | N/A | N/A | N/A |
| Price To Earnings Ratio | N/A | N/A | N/A | N/A |
| Price To Sales Ratio | N/A | N/A | N/A | N/A |
| Shares Outstanding | N/A | N/A | N/A | N/A |
| Market Capitalization | N/A | N/A | N/A | N/A |